Table 2 Baseline clinical characteristics of participants
Items | Type 1 | Type 2 |
|---|---|---|
Number (male/female) | 10 (5/5) | 20 (11/9) |
Age (years) | 52.1 ± 15.3 | 61.9 ± 13.1 |
BMI (kg/m2) | 22.2 ± 2.7 | 24.7 ± 4.8 |
Duration of diabetes (years) | 7.5 ± 4.2 | 14.6 ± 7.6 |
HbA1c (%) | 8.2 ± 1.4 | 7.6 ± 1.2 |
Prior treatment insulin | ||
Insulin glargine | 8 (80 %) | 13 (65 %) |
Insulin detemir | 2 (20 %) | 7 (35 %) |
Bolus insulin | 10 (100 %) | 7 (35 %) |
The frequency of injections with basal insulin before switching | ||
Once | 3 (30 %) | 13 (65 %) |
Twice | 7 (70 %) | 7 (35 %) |
Other concomitant drugs | ||
Glucagon like peptide-1 receptor agonist | 0 (0 %) | 0 (0 %) |
Sulphonylurea | 0 (0 %) | 2 (10 %) |
Glinide | 0 (0 %) | 7 (35 %) |
Metformin | 0 (0 %) | 10 (50 %) |
Pioglitazone | 0 (0 %) | 2 (10 %) |
α-glucosidase inhibitor | 0 (0 %) | 5 (25 %) |
Dipeptidyl peptidase 4 inhibitor | 0 (0 %) | 8 (40 %) |
Sodium glucose cotransporter 2 inhibitor | 0 (0 %) | 0 (0 %) |